OTC: EDTXF - Spectral Medical Inc.

Rentabilität für sechs Monate: +29.5%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Spectral Medical Inc.


Über das Unternehmen Spectral Medical Inc.

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.

weitere details
It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

ISIN CA8475771033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Див.доход ао 57.14
Дивиденд ао 0.12
Сайт https://spectraldx.com
Цена ао 0.525
Preisänderung pro Tag: +2.27% (0.528)
Preisänderung pro Woche: +10.2% (0.49)
Preisänderung pro Monat: +11.34% (0.485)
Preisänderung über 3 Monate: +44.39% (0.374)
Preisänderung über sechs Monate: +29.5% (0.417)
Preisänderung pro Jahr: +67.05% (0.32325)
Preisänderung über 3 Jahre: +98.53% (0.272)
Preisänderung über 5 Jahre: +89.47% (0.285)
Preisänderung seit Jahresbeginn: +67.7% (0.322)

Unterschätzung

Name Bedeutung Grad
P/S 61.02 1
P/BV -5.06 0
P/E 0 0
EV/EBITDA -12.65 0
Gesamt: 2

Effizienz

Name Bedeutung Grad
ROA, % -292.51 0
ROE, % 69.86 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0.5 5
Gesamt: 2.35

Pflicht

Name Bedeutung Grad
Debt/EBITDA -1.25 10
Gesamt: 9

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 8.81 2
Rentabilität Ebitda, % 36.22 5
Rentabilität EPS, % 37.49 5
Gesamt: 6

Institutionen Volumen Aktie, %
Benedetti & Gucer, Inc. 22200 0.01



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Christopher Seto CEO, CFO & Director 351.22k
Dr. John A. Kellum M.D. Chief Medical Officer 325.75k

Adresse: Canada, Toronto, 135 The West Mall - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://spectraldx.com